BeOne Medicines Ltd. (Stock Code: 06160) announced the entry into a Facilities Agreement on November 13, 2025, with The Hongkong and Shanghai Banking Corporation Limited (HSBC) and a syndicate of lenders. Under this agreement, BeOne Medicines Ltd. gains access to three distinct loan facilities:

The B Loan Facilities comprise (i) a US-dollar-denominated revolving loan facility of US$140 million (B1) and (ii) a US-dollar-denominated term loan facility of US$560 million (B2). These collectively amount to US$700 million and include an uncommitted option that could allow the B Loan Facilities to increase, subject to the agreement's outlined conditions. Additionally, a Renminbi-denominated A Loan Facility provides approximately RMB300 million.

The Facilities Agreement designates that proceeds may be used for general corporate obligations, refinancing existing debt, and financing related fees and expenses. The loan package features varying interest rates, which apply a margin of 0.65% per annum above the RMB reference rate for the A Loan Facility and 2.40% per annum above the USD reference rate for the B Loan Facilities. The arrangement also includes standard covenants on repayment schedules, security interests, guarantees, and conditions precedent, as well as customary events of default.

According to the announcement, the initial utilization of any loan facility depends on satisfying the agreement’s conditions precedent, including required regulatory approvals. The Facilities Agreement specifies that all obligations under these loan facilities are secured by certain assets of BeOne Medicines Ltd. and several guarantors within the group.